VBI Vaccines Inc/BC Selling, General and Administrative Expense
VBI Vaccines Inc/BC reported Selling, General and Administrative Expense of $7.67 million for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2024-05-15
- VBI Vaccines Inc/BC selling, general and administrative expense for the quarter ending 2024-03-31 was $7.67M, a 42.25% decline year-over-year.
- VBI Vaccines Inc/BC selling, general and administrative expense for the quarter ending 2023-12-31 was $8.91M, a 43.94% decline year-over-year.
- VBI Vaccines Inc/BC selling, general and administrative expense for the quarter ending 2023-09-30 was $9.04M, a 36.46% decline year-over-year.
- VBI Vaccines Inc/BC selling, general and administrative expense for the quarter ending 2023-06-30 was $10.92M, a 27.63% decline year-over-year.
- VBI Vaccines Inc/BC selling, general and administrative expense for fiscal 2023 was $42.14M, a 24.91% decline from fiscal 2022.
- VBI Vaccines Inc/BC selling, general and administrative expense for fiscal 2022 was $56.12M, a 46.39% increase from fiscal 2021.
- VBI Vaccines Inc/BC selling, general and administrative expense for fiscal 2021 was $38.34M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2024-03-31 | $7.67M 10-Q · filed 2024-05-15 | $16.58M derived: sum of 2 quarters · filed 2024-05-15 | $25.61M derived: sum of 3 quarters · filed 2024-05-15 | $36.53M derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-12-31 | $8.91M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | $17.94M derived: sum of 2 quarters · filed 2024-04-16 | $28.86M derived: sum of 3 quarters · filed 2024-04-16 | $42.14M 10-K · filed 2024-04-16 |
| 2023-09-30 | $9.04M 10-Q · filed 2023-11-14 | $19.95M derived: sum of 2 quarters · filed 2023-11-14 | $33.24M 10-Q · filed 2023-11-14 | $49.12M derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-06-30 | $10.92M 10-Q · filed 2023-08-14 | $24.20M 10-Q · filed 2023-08-14 | $40.09M derived: sum of 3 quarters · filed 2024-05-15 | $54.31M derived: sum of 4 quarters · filed 2024-05-15 |
| 2023-03-31 | $13.28M 10-Q · filed 2024-05-15 | $29.17M derived: sum of 2 quarters · filed 2024-05-15 | $43.39M derived: sum of 3 quarters · filed 2024-05-15 | $58.47M derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $15.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-16 | $30.11M derived: sum of 2 quarters · filed 2024-04-16 | $45.19M derived: sum of 3 quarters · filed 2024-04-16 | $56.12M 10-K · filed 2024-04-16 |
| 2022-09-30 | $14.22M 10-Q · filed 2023-11-14 | $29.30M derived: sum of 2 quarters · filed 2023-11-14 | $40.23M 10-Q · filed 2023-11-14 | |
| 2022-06-30 | $15.08M 10-Q · filed 2023-08-14 | $26.01M 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $10.93M 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | $38.34M 10-K · filed 2023-03-13 |